Background Oral treatment options for disease-modifying therapy in relapsing multiple
sclerosis have substantially increased over the past decade with four approved oral …

Multiple sclerosis (MS) is an autoimmune and chronic inflammatory demyelinating disease
of the central nervous system (CNS), which gives rise to focal lesion in CNS and cause …

Importance Treatment strategies for relapsing-remitting multiple sclerosis (RRMS) vary
markedly between Denmark and Sweden. The difference in the association of these national …

Objective Oral immunotherapies have become a standard treatment in relapsing-remitting
multiple sclerosis. Direct comparison of their effect on relapse and disability is needed …

Introduction Diroximel fumarate (DRF) is an oral fumarate for relapsing multiple sclerosis
(MS) with the same active metabolite as dimethyl fumarate (DMF). DRF has a safety/efficacy …

Background Comparative effectiveness (CE) research allows real-world treatment
comparisons using outcome measurements important to physicians/patients. This German …

Objective To evaluate relapse rates and disease-modifying drug (DMD) treatment in US
women with multiple sclerosis (MS) and a live birth. Methods This retrospective …

Background Previous real-world comparative research of MS disease modifying therapies
(DMTs) in the overall population has suggested dimethyl fumarate (DMF) to be comparable …

Objective To compare on-treatment efficacy and discontinuation outcomes in teriflunomide
(TFL) and dimethyl fumarate (DMF) in the treatment of relapsing-remitting multiple sclerosis …

Objective In this study, we compared the effectiveness of teriflunomide (TRF) and dimethyl
fumarate (DMF) on both clinical and MRI outcomes in patients followed prospectively in the …